Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity
Authors:
- 1 February 1991
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 65 (2) , 996-1001
Abstract
Cell surface-associated viral glycoproteins are thought to play a major role as target antigens in cellular cytotoxicity and antiviral immunosurveillance. One such glycoprotein is the Epstein-Barr virus (EBV)-encoded glycoprotein 350 (gp350), which is expressed on both virion envelope and EBV producer cells and carries the virus attachment protein moiety. Although it is known that some antibodies to gp350 can neutralize the virus, the role of this glycoprotein in EBV-specific cellular cytotoxicity is not yet clear. We describe here a study in which we successfully used a new approach to demonstrate that gp350 is a target antigen for EBV-specific antibody-dependent cellular cytotoxicity (ADCC). Transfection of gp350-negative cells resistant to natural killer (NK) cell activity (i.e., Raji) with a recombinant vector (pZIP-MA) containing the gene encoding the EBV-gp350 and the neomycin resistance gene enabled us to isolate cell clones with a stable and strong expression of gp350 on their surface membranes. ADCC determined by using two clones clearly demonstrated that gp350 is the target of the EBV ADCC. Interestingly, this ADCC was comparable to that obtained against the EBV-superinfected (coated) Raji cell expressing the same percentage of gp350 positivity as the two clones. No cytotoxic activity was detected against either nontransfected (gp350-negative) Raji cells or cells transfected with the vector [pZIP-neo-SV(X)1] lacking the gp350 gene. In addition to demonstrating that gp350 is a target molecule for EBV-specific ADCC, our approach in using NK-resistant transfectants provides a lead for probing the role of cell surface-associated viral antigens in specific cellular killing and immunosurveillance.Keywords
This publication has 22 references indexed in Scilit:
- Lysis of P3HR-1 cells induced to enter the viral cycle by antibody-dependent and independent immunological mechanismsCellular Immunology, 1989
- Antigenic analysis of the epstein-barr virus major membrane antigen (gp350/220) expressed in yeast and mammalian cells: Implications for the development of a subunit vaccineVirology, 1988
- Recombinant vaccinia virus expressing epstein‐barr virus glycoprotein gp340 protects cottontop tamarins against EB virus‐induced malignant lymphomasJournal of Medical Virology, 1988
- T-Cell Lymphomas Containing Epstein–Barr Viral DNA in Patients with Chronic Epstein–Barr Virus InfectionsNew England Journal of Medicine, 1988
- Epstein-barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosisCell, 1987
- Varicella-zoster virus as a live vector for the expression of foreign genes.Proceedings of the National Academy of Sciences, 1987
- Epitope Mapping of the Major Epstein-Barr Virus Outer Envelope Glycoprotein gp350/220Journal of General Virology, 1987
- Epstein-Barr Virus (EBV)-Lymphoid Cell Interactions. I. Quantification of EBV Particles Required for the Membrane Immunofluorescence Assay and the Comparative Expression of EBV Receptors on Different Human B, T and Null Cell LinesJournal of General Virology, 1981
- IgA antibody, antibody‐dependent cellular cytotoxicity and prognosis in patients with nasopharyngeal carcinomaInternational Journal of Cancer, 1981
- A study of malignant tumours in Nigeria by short-term tissue cultureJournal of Clinical Pathology, 1965